Interim CFO Drexler resigns; Garner appointed PFO/PAO, will depart May 15, 2024

Rein Therapeutics, Inc.

Susan L. Drexler resigned as Interim CFO, PFO and PAO effective March 25, 2024; remains consultant via Danforth Advisors.
Charles Garner appointed as principal financial officer and principal accounting officer effective March 25, 2024.
Garner's employment ends May 15, 2024; he will receive 12 months base salary severance if not terminated for cause or he quits without good reason before then.
Garner previously SVP Finance since Oct 2023, former CFO of Lung Therapeutics (acquired by Aileron).
No permanent CFO replacement announced; leadership transition in finance.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles Garner

principal financial officer and principal accounting officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-03-25
Filed: March 29, 2024, 7:59 PM ET

the Board of Directors of the Company appointed Charles Garner to serve as the Company’s principal financial officer and principal accounting officer, effective as of March 25, 2024.

Departed (interim)

Susan L. Drexler

Interim Chief Financial Officer, principal financial officer and principal accounting officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-03-25
Successor: Charles Garner
Filed: March 29, 2024, 7:59 PM ET

On March 25, 2024, Susan L. Drexler, Interim Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc. (the “Company”), notified the Company of her resignation, effective as of March 25, 2024.

Departed

Charles Garner

principal financial officer and principal accounting officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-05-15
Filed: March 29, 2024, 7:59 PM ET

Separately, the Company and Mr. Garner have agreed that his employment with the Company will end effective as of May 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Garner was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

the Board of Directors of the Company appointed Charles Garner to serve as the Company’s principal financial officer and principal accounting officer, effective as of March 25, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan L. Drexler resigned as Interim Chief Financial Officer, principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

Action: resigned
Role: Interim Chief Financial Officer, principal financial officer and principal accounting officer

Exact text from the filing

On March 25, 2024, Susan L. Drexler, Interim Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc. (the “Company”), notified the Company of her resignation, effective as of March 25, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Garner departed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..

Action: agreed that his employment will end
Role: principal financial officer and principal accounting officer

Exact text from the filing

Separately, the Company and Mr. Garner have agreed that his employment with the Company will end effective as of May 15, 2024.

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-081562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.